European Society for Medical Oncology Congress (ESMO)

In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.

The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.

Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.

Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

The primary end point of progression-free survival was met with retifanlimab to carboplatin and paclitaxel in patients with metastatic SCAC.

The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.

Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.

BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.

Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.

Objective response rate appears to be higher with datopotamab deruxtecan compared with docetaxel among patients with advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 study.

Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.

Data from the phase 3 KEYNOTE-775 trial support lenvatinib plus pembrolizumab as a standard therapy option for patients with previously treated advanced endometrial cancer.

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.